Simeprevir, also known as TMC43, is a drug for the treatment and cure of hepatitis C. In the United States, simeprevir is approved by the Food and Drug Administration for use in combination with peginterferon-alfa and ribavirin for hepatitis C and hepatitis B. Simeprevir has been approved in Japan for the treatment of chronic hepatitis C infection, genotype 1.
HCV Protease Inhibitors Related Prodcuts:
Daclatasvir; Daclatasvir hcl; Telaprevir; Lomibuvir; Danoprevir; Paritaprevir; Paritaprevir dihydrate; Grazoprevir; Elbasvir; Ombitasvir; Velpatasvir; Ledipasvir; Boceprevir